NextCure holder ADAR1 funds buy 17,608 shares

NextCure, Inc. had open-market purchases of its common stock reported by 10% owners ADAR1 Capital Management, LLC and Daniel Schneeberger.

Rhea-AI Filing Summary

NextCure, Inc. had open-market purchases of its common stock reported by 10% owners ADAR1 Capital Management, LLC and Daniel Schneeberger. Private investment funds managed by ADAR1 bought 17,608 shares between July 27 and July 29, 2026, at prices around $4.90–$5.00 per share. The securities are owned directly by those funds and may be deemed indirectly beneficially owned by ADAR1 and Schneeberger, who each disclaim beneficial ownership except to the extent of any pecuniary interest.

Insider Trade Summary

Net Buyer: 17,608 shares

Net Buy 4 txns

Insider ADAR1 Capital Management, LLC, Schneeberger Daniel

Role 10% Owner | 10% Owner

Bought 17,608 shs ($88K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F2, F3	1,810	$5.00	$9K
Purchase	Common Stock F2, F3	1,600	$5.00	$8K
Purchase	Common Stock F1, F2, F3	6,400	$4.9496	$32K
Purchase	Common Stock F2, F3	7,798	$4.9994	$39K

Holdings After Transaction: Common Stock — 393,266 shares (Indirect, See Footnote)

Footnotes (3)

1. F1. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9000 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
2. F2. The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
3. F3. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Key Figures

Total shares purchased: 17,608 shares Price range (weighted average trade): $4.9000–$5.0000 per share Purchase on July 27, 2026: 7,798 shares at $4.9994 per share +2 more

5 metrics

Total shares purchased 17,608 shares Open-market purchases by private funds managed by ADAR1 between July 27–29, 2026

Price range (weighted average trade) $4.9000–$5.0000 per share Range of prices for the July 28, 2026 purchases described as a weighted average

Purchase on July 27, 2026 7,798 shares at $4.9994 per share Indirectly held through private investment funds managed by ADAR1

Purchase on July 28, 2026 6,400 shares at $4.9496 per share Part of multiple transactions reported with a weighted average price disclosure

Purchases on July 29, 2026 1,810 shares and 1,600 shares at $5.0000 per share Two indirect open-market purchases of NextCure common stock

Key Terms

weighted average price, indirectly beneficially owned, pecuniary interest, Section 16 of the Securities Exchange Act of 1934

4 terms

weighted average price financial

"The reported price is a weighted average price. These shares were purchased..."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

indirectly beneficially owned regulatory

"may be deemed to be indirectly beneficially owned by ADAR1 Capital Management, LLC..."

pecuniary interest regulatory

"disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest..."

Section 16 of the Securities Exchange Act of 1934 regulatory

"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended..."

A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share purchases did NXTC report for late July 2026?

Investment funds managed by ADAR1 Capital Management reported buying 17,608 shares of NextCure common stock between July 27 and July 29, 2026. The open-market purchases were made at prices around $4.90–$5.00 per share and are reported under Section 16.

Who are the reporting persons in the latest NXTC insider transactions?

The reporting persons are ADAR1 Capital Management, LLC and Daniel Schneeberger, each listed as a 10% owner. The reported NextCure shares are owned directly by private investment funds managed by ADAR1, which may be deemed indirectly beneficially owned by the reporting persons.

At what prices were the recent NXTC shares purchased by ADAR1-managed funds?

The reported purchases include a weighted average price for one date, with trades executed between $4.9000 and $5.0000 per share. Individual transactions show prices such as $4.9496 and $5.0000 per share for the common stock.

How many NXTC shares were bought in each reported transaction?

Reported purchases include 7,798 shares on July 27, 2026, 6,400 shares on July 28, 2026, and two trades of 1,810 and 1,600 shares on July 29, 2026. In total, private funds managed by ADAR1 acquired 17,608 shares of NextCure common stock.

Do the NXTC reporting persons claim full beneficial ownership of the purchased shares?

No. The filing states the securities are owned directly by private investment funds managed by ADAR1 and may be deemed indirectly beneficially owned. Each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest in those securities.

Were the July 2026 NXTC insider trades made under a Rule 10b5-1 trading plan?

The document-level Rule 10b5-1 checkbox is not marked as being pursuant to such a plan. The disclosure does not describe these transactions as executed under a Rule 10b5-1 trading arrangement, focusing instead on ownership by ADAR1-managed private funds.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 06:19 PM Accepted by SEC EDGAR 07/29/2026 - 06:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ADAR1 Capital Management, LLC

(Last) (First) (Middle)

3503 WILD CHERRY DRIVE

BUILDING 9

(Street)

AUSTIN TEXAS 78738

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NextCure, Inc. [ NXTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/27/2026		P		7,798	A	$4.9994	383,456	I	See Footnote(2)(3)
Common Stock	07/28/2026		P		6,400	A	$4.9496(1)	389,856	I	See Footnote(2)(3)
Common Stock	07/29/2026		P		1,810	A	$5	391,666	I	See Footnote(2)(3)
Common Stock	07/29/2026		P		1,600	A	$5	393,266	I	See Footnote(2)(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

ADAR1 Capital Management, LLC

(Last) (First) (Middle)

3503 WILD CHERRY DRIVE

BUILDING 9

(Street)

AUSTIN TEXAS 78738

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Schneeberger Daniel

(Last) (First) (Middle)

3503 WILD CHERRY DRIVE

BUILDING 9

(Street)

AUSTIN TEXAS 78738

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9000 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

2. The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

3. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

	ADAR1 Capital Management, LLC By: Daniel Schneeberger, Manager /s/ Daniel Schneeberger	07/29/2026
	/s/ Daniel Schneeberger	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)